Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
|Videos|January 13, 2014
An Overview of the I-SPY 2 Trial
Author(s)Laura J. Esserman, MD
Laura J. Esserman, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.
Advertisement
Clinical Pearls
Laura J. Esserman, MD, professor, Departments of Surgery and Radiology, affiliate faculty, Institute for Health Policy Studies, University of California, San Francisco, director, Carol Franc Buck Breast Care Center; co-leader, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.
- Pharmaceutical companies, diagnostic companies, academic institutions, and professionals worked together to evaluate drugs by class
- Veliparib in combination with carboplatin showed benefit in triple-negative breast cancer
- Researchers believe a phase III trial of veliparib plus carboplatin will be successful
Advertisement
Related to this article
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
4
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
5